Schiebel Johannes, Radeva Nedyalka, Krimmer Stefan G, Wang Xiaojie, Stieler Martin, Ehrmann Frederik R, Fu Kan, Metz Alexander, Huschmann Franziska U, Weiss Manfred S, Mueller Uwe, Heine Andreas, Klebe Gerhard
Institut für Pharmazeutische Chemie, Philipps-Universität Marburg , Marbacher Weg 6, 35032 Marburg, Germany.
Helmholtz-Zentrum Berlin für Materialien und Energie, HZB , BESSY II, Abteilung Makromolekulare Kristallographie, Albert-Einstein-Str. 15, 12489 Berlin, Germany.
ACS Chem Biol. 2016 Jun 17;11(6):1693-701. doi: 10.1021/acschembio.5b01034. Epub 2016 Apr 8.
Fragment-based lead discovery (FBLD) has become a pillar in drug development. Typical applications of this method comprise at least two biophysical screens as prefilter and a follow-up crystallographic experiment on a subset of fragments. Clearly, structural information is pivotal in FBLD, but a key question is whether such a screening cascade strategy will retrieve the majority of fragment-bound structures. We therefore set out to screen 361 fragments for binding to endothiapepsin, a representative of the challenging group of aspartic proteases, employing six screening techniques and crystallography in parallel. Crystallography resulted in the very high number of 71 structures. Yet alarmingly, 44% of these hits were not detected by any biophysical screening approach. Moreover, any screening cascade, building on the results from two or more screening methods, would have failed to predict at least 73% of these hits. We thus conclude that, at least in the present case, the frequently applied biophysical prescreening filters deteriorate the number of possible X-ray hits while only the immediate use of crystallography enables exhaustive retrieval of a maximum of fragment structures, which represent a rich source guiding hit-to-lead-to-drug evolution.
基于片段的先导化合物发现(FBLD)已成为药物研发的一个支柱。该方法的典型应用包括至少两个作为预筛选的生物物理筛选以及对一部分片段进行后续的晶体学实验。显然,结构信息在FBLD中至关重要,但一个关键问题是,这样的筛选级联策略是否能找出大多数片段结合结构。因此,我们着手采用六种筛选技术并同时结合晶体学,对361个片段与内皮抑素(一种具有挑战性的天冬氨酸蛋白酶代表)的结合情况进行筛选。晶体学得到了多达71个结构。然而,令人担忧的是,这些命中结果中有44%未被任何生物物理筛选方法检测到。此外,基于两种或更多筛选方法结果构建的任何筛选级联都无法预测至少73%的这些命中结果。我们因此得出结论,至少在当前情况下,频繁应用的生物物理预筛选过滤器减少了可能的X射线命中结果数量,而只有直接使用晶体学才能全面检索出最多的片段结构,这些结构是引导从命中到先导再到药物演变的丰富来源。